Kurt Von Emster

Iambic is a clinical-stage AI biotech developing novel medicines using its AI-driven platform. Based in San Diego and founded in 2020, Iambic has assembled a world-class team that unites pioneering AI experts and experienced drug hunters. The Iambic platform has demonstrated delivery of new drug candidates to human clinical trials with industry-leading speed and across multiple target classes and mechanisms of action. Iambic is advancing a pipeline of potential best-in-class and first-in-class clinical assets to address urgent unmet patient need. Learn more at iambic.ai

Tizona Therapeutics, Inc., is an immunology company harnessing the power of the immune system to develop treatments for cancer and autoimmune diseases. Founded by MPM Capital and leading scientists from Dana Farber Cancer Institute, the University of Pittsburgh, Johns Hopkins, Memorial Sloan Kettering Cancer Center, and Brigham and Women’s Hospital, Tizona’s therapies are designed to modulate the activity of immunosuppressive cells, thereby activating the body’s ability to fight cancer or preventing the immune system from attacking healthy tissues in autoimmune diseases. Our programs target the cell types and biological mechanisms responsible for immune suppression in the tumor microenvironment and for controlling self-reactivity in autoimmunity. For more information, please email info@tizonatx.com.

Jasper Therapeutics is a biotechnology company on a mission to make safer and potentially curative therapy possible for more patients in need. We are bringing together a team of biotech veterans, leading academic institutions and a strong syndicate of healthcare-focused investors to achieve our vision of developing new therapies for diseases of mast and stem cells, and safer and more effective conditioning for monogenetic diseases.

Attenua, Inc. is a virtual biotech company formed to develop therapies for debilitating conditions neglected by Big Pharma's shift to specialty Pharma and biologics. We believe small molecule Blockbuster drugs that would benefit millions are still to be discovered. We have assembled a team of leading scientists and ex-Big Pharma advisors with many years of drug development expertise. Our team has previous work experience at Merck, GSK, AstraZeneca, and Genentech. Our team has 117 years of combined drug development experience.

Kesios Therapeutics Limited is a UK-based biotechnology company developing novel therapeutics for the treatment of multiple myeloma and other cancers where there are significant unmet medical needs. The company is focused on the discovery and development of novel drug candidates for the treatment of multiple myeloma and other malignancies which target aberrant NF-κB signaling, via a novel drug target (the GADD45β/MKK7 complex). The NF-κB signaling pathway is involved in driving normal cell death but when aberrantly activated allows cancer cells to survive. The company has established a pipeline of programmes targeting this pathway, with KES-0001, the company’s lead drug candidate, about to enter clinical studies as a potential treatment for multiple myeloma. Additional pre-clinical research programmes will explore KES-0001 in haematological malignancies, colon cancer and other solid tumors. Kesios is led by an experienced management team and is supported by a syndicate of leading international investors. The company operates from offices and laboratories based at the Imperial College Incubator, London, UK.

Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. The Company is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Vaxcyte’s lead candidate, VAX-24, is a 24-valent, broad-spectrum pneumococcal conjugate vaccine being developed for the prevention of invasive pneumococcal disease. Vaxcyte is re-engineering the way highly complex immunizations are made through modern synthetic techniques, including advanced chemistry and the XpressCFᵀᴹ cell-free protein synthesis platform, exclusively licensed from Sutro Biopharma, Inc. Unlike conventional cell-based approaches, the Company’s system for producing difficult-to-make proteins and antigens is intended to accelerate its ability to efficiently create and deliver high-fidelity vaccines with enhanced immunological benefits. Vaxcyte’s pipeline also includes VAX-31, a PCV with an expanded breadth of coverage of greater than 30 strains; VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections; VAX-PG, a therapeutic vaccine candidate designed to slow or stop the progression of periodontal disease and VAX-GI, a novel preclinical vaccine candidate being developed as a preventative treatment for dysentery and shigellosis. Vaxcyte is driven to eradicate or treat invasive bacterial infections, which have serious and costly health consequences when left unchecked.

Iambic is a clinical-stage AI biotech developing novel medicines using its AI-driven platform. Based in San Diego and founded in 2020, Iambic has assembled a world-class team that unites pioneering AI experts and experienced drug hunters. The Iambic platform has demonstrated delivery of new drug candidates to human clinical trials with industry-leading speed and across multiple target classes and mechanisms of action. Iambic is advancing a pipeline of potential best-in-class and first-in-class clinical assets to address urgent unmet patient need. Learn more at iambic.ai

Tizona Therapeutics, Inc., is an immunology company harnessing the power of the immune system to develop treatments for cancer and autoimmune diseases. Founded by MPM Capital and leading scientists from Dana Farber Cancer Institute, the University of Pittsburgh, Johns Hopkins, Memorial Sloan Kettering Cancer Center, and Brigham and Women’s Hospital, Tizona’s therapies are designed to modulate the activity of immunosuppressive cells, thereby activating the body’s ability to fight cancer or preventing the immune system from attacking healthy tissues in autoimmune diseases. Our programs target the cell types and biological mechanisms responsible for immune suppression in the tumor microenvironment and for controlling self-reactivity in autoimmunity. For more information, please email info@tizonatx.com.

The SFJ Pharmaceuticals Group is a Specialty Pharma Company deploying a new business model for the clinical development and registration of pharmaceutical products. Established in 2009, SFJ provides a financially advantageous and creative alternative approach to partnering. SFJ can provide the strategic financing, clinical development and regulatory resources for the clinical development and approval or your products. SFJ is staffed with a seasoned team of professionals, with extensive experience in the clinical development and regulatory approval of pharmaceutical products on a global basis. SFJ has offices in the United States, Europe, Japan, Singapore, Caymans, and Korea.